Use of Paclitaxel Associated to Lipid Core Nanoparticles (LDE) in the Second or Third Line Treatment of Advanced Pancreatic Adenocarcinoma
Abstract:Background: Previously, we showed that paclitaxel carried in non-protein Lipid Core Nanoparticles (LDE) resembling the lipid structure of LDL has remarkably reduced toxicity in patients with advanced solid cancers, as used in 3 rd line chemotherapy or further. The aim was to test LDE-paclitaxel treatment in progressive, advanced pancreatic adenocarcinoma as second or third line of therapy.Methods: This was a prospective, single-arm study enrolling patients that had been previously submitted to at least one sta… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.